

New service for patients with recurrent C-diff infections

OHSU clinicians who provide care for the approximately 400 OHSU patients a year with recurrent *Clostridium difficile* infection (R-CDI) have a new treatment option to consider. Fecal microbiota transplantation (FMT) is now available for both adult and pediatric patients. *Clostridium difficile* infection (CDI) is a leading cause of antibiotic-associated diarrhea in the United States. Over the past decade, fecal microbiota transplantation (FMT) has become a treatment of choice for R-CDI. FMT involves administration of healthy donor fecal preparation into the gastrointestinal tract of a patient. In adults, the overall cure rate of CDI with FMT is nearly 95 percent. Pediatric experience with FMT is more limited; however, cure rates in children appear to be similar to adult rates.

The FDA published guidelines in 2013 stating that FMT for R-CDI may proceed at institutions under informed consent. Five OHSU providers are currently authorized to administer FMT. These providers are specialists in infectious diseases and gastroenterology for either adult or pediatric patients.

For more information, review the FMT resources below or contact the appropriate School of Medicine faculty members:

Pediatric inquiries: Dawn Nolt, M.D., MPH, clinical associate professor of pediatrics (Division of Pediatric Infectious Diseases)

Adult inquiries: Morgan Hakki, M.D., assistant professor of medicine (Division of Infectious Diseases)